z-logo
open-access-imgOpen Access
The Th2‐response in mercuric chloride‐induced autoimmunity requires continuing costimulation via CD28 *
Author(s) -
MACPHEE I. A. M.,
TURNER D. R.,
YAGITA H.,
OLIVEIRA D.B.G.
Publication year - 2002
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.2002.01928.x
Subject(s) - autoimmunity , immunology , medicine , immune system
SUMMARY Mercuric chloride (HgCl 2 )‐induced autoimmunity in Brown Norway (BN) rats is a highly polarized polyclonal Th2‐driven autoimmune response with increased IgE production, lymphoproliferation, vasculitis and proteinuria. The increase in serum IgE concentration is clearly measurable by day 4 after the first HgCl 2 injection and peaks between days 15 and 20. Treatment with CD80 and CD86 antibodies prior to administration of HgCl 2 completely suppresses the autoimmune process. To determine whether interruption of CD28 signalling after initial stimulation of the Th2‐response would be suppressive, antibody treatment was delayed. BN rats were given 5 doses of HgCl 2 subcutaneously on alternate days. CD80 and CD86 antibodies, or an isotype control, were given daily for 3 days and then on alternate days until day 12 commencing either on the day of the first HgCl 2 injection (day 0) or on days 4 or 8. Treatment from day 0 reduced serum IgE concentrations to below baseline (median 9·34μg/ml on day 0 versus 4·6μg/ml, on day 5, P = 0·03) suggesting that ongoing costimulation via CD28 is required to maintain basal serum IgE production. Delaying treatment until day 4 or day 8 after the first HgCl 2 injection resulted in significant inhibition of IgE secretion, lymphoproliferation, and vasculitis, although less markedly than when treatment was commenced on day 0. These data indicate that CD28‐mediated costimulation is not only required for the initiation of the Th2‐response but is required for maintenance of a maximal response, making this an attractive therapeutic target for antibody‐mediated autoimmune diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom